<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719111415546</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719111415546</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nuclear Receptor, Coregulator Signaling, and Chromatin Remodeling Pathways Suggest Involvement of the Epigenome in the Steroid Hormone Response of Endometrium and Abnormalities in Endometriosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zelenko</surname>
<given-names>Z.</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="aff1-1933719111415546">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aghajanova</surname>
<given-names>L.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111415546">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Irwin</surname>
<given-names>J. C.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111415546">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Giudice</surname>
<given-names>Linda C.</given-names>
</name>
<degrees>MD, PhD, MSc</degrees>
<xref ref-type="aff" rid="aff1-1933719111415546">1</xref>
<xref ref-type="corresp" rid="corresp1-1933719111415546"/>
</contrib>
</contrib-group>
<aff id="aff1-1933719111415546">
<label>1</label>Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA</aff>
<author-notes>
<corresp id="corresp1-1933719111415546">Linda C. Giudice, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, 505 Parnassus Ave., M1496, Box 0132, San Francisco, CA 94143, USA Email: <email>giudice@obgyn.ucsf.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>152</fpage>
<lpage>162</lpage>
<permissions>
<copyright-statement>© Society for Gynecologic Investigation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Human endometrium, a steroid hormone-dependent tissue, displays complex cellular regulation mediated by nuclear receptors (NRs). The NRs interact with histone-modifying and DNA-methylating/-demethylating enzymes in the transcriptional complex. We investigated NRs, their coregulators, and associated signaling pathways in endometrium across the normal menstrual cycle and in endometriosis, an estrogen-dependent, progesterone-resistant disorder. Endometrial tissue was processed for analysis of 84 genes using NR and coregulator polymerase chain reaction (PCR) arrays. Select genes were validated by immunohistochemistry. Ingenuity pathway analysis identified DNA methylation and transcriptional repression signaling as the most affected pathway in endometrium in women with versus without endometriosis, regardless of cycle phase. Thyroid hormone receptor (THR) and vitamin D receptor (VDR) pathways were also regulated in normal and disease endometrium by activation of TH or vitamin D regulated genes. These data support the involvement of the epigenome in steroid hormone response of normal endometrium throughout the cycle and abnormalities in endometrium in women with endometriosis.</p>
</abstract>
<kwd-group>
<kwd>endometriosis</kwd>
<kwd>nuclear receptors</kwd>
<kwd>coregulators</kwd>
<kwd>DNA methylation</kwd>
<kwd>histone deacetylases</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719111415546">
<title>Introduction</title>
<p>Steroid hormone-responsive tissues display complex regulation of tissue-specific cellular functions mediated by nuclear receptors (NRs). The involvement of NRs with coregulators and other recruited proteins in the transcriptional complex is essential for target gene regulation.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111415546">1</xref>
</sup> The NRs interact with histone-modifying enzymes and DNA-methylating/-demethylating enzymes in the transcriptional complex, and histone modification and DNA methylation are interrelated in regulating gene expression and chromatin remodeling.<sup>
<xref ref-type="bibr" rid="bibr2-1933719111415546">2</xref>,<xref ref-type="bibr" rid="bibr3-1933719111415546">3</xref>
</sup> Thus, steroid hormone-responsive tissues have epigenetic constituents regulating normal physiologic functions, which may be vulnerable to modifications that alter these intended functions, resulting in human disease.</p>
<p>Human endometrium is a steroid hormone-responsive tissue whose cellular components, in response to cyclic changes in circulating ovarian-derived estradiol (E<sub>2</sub>) and progesterone (P<sub>4</sub>), undergo proliferation, angiogenesis, differentiation, and apoptosis, in preparation of embryonic implantation. Abnormalities in endometrial steroid hormone responsiveness have profound effects on pregnancy establishment, maintenance, and outcomes and result in infertility, miscarriage, and pregnancy complications, as well as cancer.<sup>
<xref ref-type="bibr" rid="bibr4-1933719111415546">4</xref>
</sup> In endometriosis, which is present in 6% to 10% of reproductive age women<sup>
<xref ref-type="bibr" rid="bibr5-1933719111415546">5</xref>
</sup> and up to 50% of women with infertility,<sup>
<xref ref-type="bibr" rid="bibr4-1933719111415546">4</xref>,<xref ref-type="bibr" rid="bibr6-1933719111415546">6</xref>
</sup> there is increasing evidence that epigenetic modifications of steroid hormone receptors (estrogen receptor 2 [<italic>ESR2</italic>], progesterone receptor B [<italic>PGRB</italic>]) and transcription factors (<italic>HOXA10, SF1</italic>) involved in steroid hormone gene regulation and biosynthesis result in resistance to P<sub>4</sub> action within the endometrium and subsequently abnormal receptivity to embryonic implantation.<sup>
<xref ref-type="bibr" rid="bibr7-1933719111415546">7</xref>
</sup> The progesterone receptor is a member of the superfamily of NRs whose transcriptional activity is regulated by various cofactors.<sup>
<xref ref-type="bibr" rid="bibr8-1933719111415546">8</xref>
</sup> Decreased expression of PGRs,<sup>
<xref ref-type="bibr" rid="bibr9-1933719111415546">9</xref>
</sup> hypermethylation of the PGRB promoter,<sup>
<xref ref-type="bibr" rid="bibr10-1933719111415546">10</xref>
</sup> abnormal regulation and expression of the PGR coactivator, Hydrogen peroxide-inducible clone-5 (<italic>HIC5</italic>),<sup>
<xref ref-type="bibr" rid="bibr11-1933719111415546">11</xref>
</sup> and local E<sub>2</sub> biosynthesis<sup>
<xref ref-type="bibr" rid="bibr6-1933719111415546">6</xref>
</sup> contribute to resistance to P<sub>4</sub> action in this tissue.<sup>
<xref ref-type="bibr" rid="bibr7-1933719111415546">7</xref>
</sup> Abrogated P<sub>4</sub> signaling results in enhanced estrogen responsiveness, with a characteristic persistent proliferative phenotype of eutopic endometrium, as well as ectopic lesions in the pelvis and is accompanied by increased cell survival and invasive capacity.<sup>
<xref ref-type="bibr" rid="bibr4-1933719111415546">4</xref>,<xref ref-type="bibr" rid="bibr6-1933719111415546">6</xref>,<xref ref-type="bibr" rid="bibr12-1933719111415546">12</xref>
</sup>
</p>
<p>In the current study, we found cycle-dependent expression of specific NRs, coregulators, and genes engaged in a complex orchestra of signaling pathways and chromatin remodeling across the menstrual cycle and dysregulation of key players in steroid hormone, thyroid hormone, and vitamin D signaling, as well as chromatin remodeling, in the presence of endometriosis. These novel findings are significant to the biology of steroid hormone action within the endometrium and likely other tissues and in the pathogenesis and pathophysiology of endometriosis.</p>
</sec>
<sec id="section2-1933719111415546">
<title>Materials and Methods</title>
<sec id="section3-1933719111415546">
<title>Tissue Collection</title>
<p>Tissue samples of proliferative (PE), early secretory (ESE), and midsecretory endometrium (MSE) were collected from hysterectomy or biopsy specimens. Control samples were obtained from women undergoing surgery for benign disease and who did not have a history of endometriosis. Endometrial tissue was immediately frozen in liquid nitrogen and then stored at −80°C. Disease samples were obtained from women who had moderate/severe endometriosis (stage III/IV). The study participants in both the disease and no disease categories were 22 to 45 years old and had regular menstrual cycles, had not been on hormonal therapy within 3 months of tissue sampling, and were documented not to be pregnant. The profile of the participant annotation is provided in <xref ref-type="table" rid="table1-1933719111415546">Table 1</xref>. All tissue samples were collected after written, informed consent, through The University of California, San Francisco (UCSF)/National Institutes of Health (NIH) Human Endometrial Tissue and DNA Bank, under full review and with approval of the Committee on Human Research of the UCSF.</p>
<table-wrap id="table1-1933719111415546" position="float">
<label>Table 1.</label>
<caption>
<p>Participant Characteristics: Disease and Control Specimens<sup><xref ref-type="table-fn" rid="table-fn7-1933719111415546">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-1933719111415546" xlink:href="10.1177_1933719111415546-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Patient ID</th>
<th colspan="7">Type of</th>
</tr>
<tr>
<th>Sample</th>
<th>Cycle Phase</th>
<th>Age (yr)</th>
<th>Diagnoses</th>
<th>Ethnicity</th>
<th>Mode of Collection</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST-84</td>
<td>Disease</td>
<td>Pro</td>
<td>37</td>
<td>PP, SE, leiomyoma</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>Hydroxyzine, flax seed oil, fish oil</td>
</tr>
<tr>
<td>508</td>
<td>Disease</td>
<td>Pro</td>
<td>25</td>
<td>PP, SE, bleeding</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>Atenolol, sorrel, burdock root</td>
</tr>
<tr>
<td>587</td>
<td>Disease</td>
<td>Pro</td>
<td>37</td>
<td>PI, SE, liver endo</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>651</td>
<td>Disease</td>
<td>Pro</td>
<td>37</td>
<td>PI, SE, endometrioma, leiomyoma</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>Advair, rhinocort</td>
</tr>
<tr>
<td>575<sup><xref ref-type="table-fn" rid="table-fn8-1933719111415546">b</xref></sup>
</td>
<td>Disease</td>
<td>Pro</td>
<td>26</td>
<td>SE, left endometrioma, pelvic adhesions</td>
<td>Unknown</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>589<sup><xref ref-type="table-fn" rid="table-fn8-1933719111415546">b</xref></sup>
</td>
<td>Disease</td>
<td>Pro</td>
<td>48</td>
<td>Bilateral endometrioma, leiomyomata</td>
<td>Asian</td>
<td>Hysterectomy</td>
<td>Cytomel</td>
</tr>
<tr>
<td>ST90<sup><xref ref-type="table-fn" rid="table-fn8-1933719111415546">b</xref></sup>
</td>
<td>Disease</td>
<td>Pro</td>
<td>42</td>
<td>PP, SE, ovary with follicular cyst</td>
<td>Caucasian</td>
<td>Pipelle Biopsy</td>
<td>
</td>
</tr>
<tr>
<td>455</td>
<td>Control</td>
<td>Pro</td>
<td>39</td>
<td>Menorrhagia, leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Levothyroxine, cytomel</td>
</tr>
<tr>
<td>469</td>
<td>Control</td>
<td>Pro</td>
<td>42</td>
<td>Leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Synthroid, motrin</td>
</tr>
<tr>
<td>604</td>
<td>Control</td>
<td>Pro</td>
<td>44</td>
<td>Uterine prolapse, cystocele, rectocele</td>
<td>Caucasian</td>
<td>Pipelle Biopsy</td>
<td>Imitrex</td>
</tr>
<tr>
<td>693</td>
<td>Control</td>
<td>Pro</td>
<td>46</td>
<td>Bladder laceration</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>
</td>
</tr>
<tr>
<td>607</td>
<td>Disease</td>
<td>ES</td>
<td>24</td>
<td>SE, bilateral ovaries, right ovarian cyst</td>
<td>Asian</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>684</td>
<td>Disease</td>
<td>ES</td>
<td>36</td>
<td>SE, leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>
</td>
</tr>
<tr>
<td>ST-112</td>
<td>Disease</td>
<td>ES</td>
<td>38</td>
<td>PP, SE, bleeding</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>ST-130</td>
<td>Disease</td>
<td>ES</td>
<td>35</td>
<td>SE, adenomyosis, right ovarian cyst</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>UC-24</td>
<td>Control</td>
<td>ES</td>
<td>45</td>
<td>Menorrhagia, leiomyomata</td>
<td>Black</td>
<td>Hysterectomy</td>
<td>Hydrochlorothiazide, topamax</td>
</tr>
<tr>
<td>UC-26</td>
<td>Control</td>
<td>ES</td>
<td>34</td>
<td>Menometrorrhagia, leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Prednisone, zyrtec, folic acid</td>
</tr>
<tr>
<td>629</td>
<td>Control</td>
<td>ES</td>
<td>46</td>
<td>Leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Iron</td>
</tr>
<tr>
<td>680</td>
<td>Control</td>
<td>ES</td>
<td>34</td>
<td>Uterine prolapse</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Zoloft, phentermine</td>
</tr>
<tr>
<td>544</td>
<td>Disease</td>
<td>MS</td>
<td>46</td>
<td>SE, endocervical polyp, leiomyoma</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>ST-37</td>
<td>Disease</td>
<td>MS</td>
<td>32</td>
<td>SE, bleeding, abnormal ovarian pathology</td>
<td>Unknown</td>
<td>Pipelle biopsy</td>
<td>
</td>
</tr>
<tr>
<td>ST-91</td>
<td>Disease</td>
<td>MS</td>
<td>20</td>
<td>PP, SE, adenomyosis, pelvic adhesions</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>Advil, percocet, metoclopraminde</td>
</tr>
<tr>
<td>ST-96</td>
<td>Disease</td>
<td>MS</td>
<td>31</td>
<td>PP, SE, PCOS, right ovarian cyst</td>
<td>Caucasian</td>
<td>Pipelle biopsy</td>
<td>Tylenol, claritin</td>
</tr>
<tr>
<td>463</td>
<td>Control</td>
<td>MS</td>
<td>48</td>
<td>Leiomyoma, prolapse</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Zyrtec, iron, elavil</td>
</tr>
<tr>
<td>501<sup><xref ref-type="table-fn" rid="table-fn9-1933719111415546">c</xref></sup>
</td>
<td>Control</td>
<td>MS</td>
<td>49</td>
<td>Leiomyoma, menorrhagia</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Prozac, calcium, iron</td>
</tr>
<tr>
<td>610</td>
<td>Control</td>
<td>MS</td>
<td>50</td>
<td>PP, hormonal imbalance</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>
</td>
</tr>
<tr>
<td>626</td>
<td>Control</td>
<td>MS</td>
<td>42</td>
<td>Prolapse, cystocele, rectocele</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Allegra, advil</td>
</tr>
<tr>
<td>648<sup><xref ref-type="table-fn" rid="table-fn9-1933719111415546">c</xref></sup>
</td>
<td>Control</td>
<td>MS</td>
<td>45</td>
<td>Leiomyoma</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>Lexapro, ambien</td>
</tr>
<tr>
<td>705<sup><xref ref-type="table-fn" rid="table-fn8-1933719111415546">b</xref></sup>
</td>
<td>Control</td>
<td>MS</td>
<td>46</td>
<td>Left ovarian cyst, dysmenorrhea</td>
<td>Caucasian</td>
<td>Hysterectomy</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1933719111415546">
<p>Abbreviations: Pro, proliferative; ES, early secretory; MS, mid-secretory; PP, pelvic pain; SE, severe endometriosis; PI, peritoneal endometriosis; PCOS, polycystic ovarian disease; endo, endometriosis; PCR, polymerase chain reaction.</p>
</fn>
<fn id="table-fn7-1933719111415546">
<p>
<sup>a</sup> All disease specimens were taken from participants surgically staged with moderate/severe endometriosis.</p>
</fn>
<fn id="table-fn8-1933719111415546">
<p>
<sup>b</sup> Sample used for Immunohistochemistry (IHC) validation but not PCR array analysis.</p>
</fn>
<fn id="table-fn9-1933719111415546">
<p>
<sup>c</sup> Sample used only for PCR array analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-1933719111415546">
<title>RNA Isolation and Complementary DNA Synthesis</title>
<p>Total RNA was isolated from PE (n = 4 with disease; n = 4 controls), ESE (n = 4 with disease; n = 4 controls), and MSE (n = 4 with disease; n = 5 controls). Menstrual cycle phase was determined by at least 2 pathologists. The endometrial tissue was processed using Trizol reagent (Invitrogen, Carlsbad, California) and purified using the NucleoSpin RNA II Kit (Marcherey-Nagel, Bethlehem, Pennsylvania), which incorporates DNase treatment in the purification process. Ribonucleic acid concentration and quality (260/280 ratio) were assessed by the Nanodrop instrument (Thermo Scientific, Wilmington, Delaware). Reverse transcription was performed on 1 μg of template to generate double-stranded complementary DNA (cDNA) using RT<sup>
<xref ref-type="bibr" rid="bibr2-1933719111415546">2</xref>
</sup> Fist Strand kit (SA Biosciences, Frederick, Maryland). The cDNA was stored at −20°C.</p>
</sec>
<sec id="section5-1933719111415546">
<title>Polymerase Chain Reaction Array and Ingenuity Pathway Analysis</title>
<p>Real-time quantitative polymerase chain reaction (RT<sup>
<xref ref-type="bibr" rid="bibr2-1933719111415546">2</xref>
</sup> qPCR) Master Mixes (SA Biosciences) were used for the human nuclear receptors and coregulators RT<sup>
<xref ref-type="bibr" rid="bibr2-1933719111415546">2</xref>
</sup> profiler PCR array (SA Biosciences). The 384-well PCR arrays were chosen with precoated primers for 84 genes of interest and 5 housekeeping genes. There were also genomic DNA controls, 3 replicate reverse transcription controls and 3 replicate positive PCR controls (SA Biosciences). The 384-well PCR array plates were run on ABI 7900HT (Applied Biosystems, Carlsbad, California) in the Genomics Core at the UCSF. The Cycle threshold (Ct) values were provided for the genes, and an online Web-based PCR array data analysis Web site provided by SA Biosciences was used to generate fold changes. ΔΔCt was generated using PCR Array Data Analysis Web Portal (SA Biosicences) and the significance for ≥1.5-fold differences was assessed by a 2-tailed <italic>t</italic> test at <italic>P</italic> ≤ .05. Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, California) evaluated the participating networks and canonical pathways.</p>
</sec>
<sec id="section6-1933719111415546">
<title>Validation by Immunohistochemistry</title>
<p>Indirect immunostaining was performed with paraffin sections of disease and no disease tissue specimens (PE, n = 3 and n = 4; ESE, n=4; and n = 4; MSE, n = 4 and n = 4, respectively) using antibodies against histone deacetylase 1 (HDAC1), thyroid hormone receptorα (THRA), and DEAD box polypeptide 5 ([DDX5] all from Abcam, Cambridge, Massachusetts). After deparaffinization and rehydration, heat-mediated antigen retrieval<sup>
<xref ref-type="bibr" rid="bibr13-1933719111415546">13</xref>
</sup> was performed in a 1× citrate buffer pH 6.0 for 15 minutes at 95°C. The sections were incubated with the primary antibodies (at concentrations: 1.25 μg/mL HDAC1; 2.5 μg/mL THRA; 2 μg/mL DDX5) in blocking buffer overnight at 4°C. Human placenta was used as a positive control, and incubation with the corresponding nonimmune immunoglobulin (Ig) isotypes used as a negative control.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111415546">14</xref>
<xref ref-type="bibr" rid="bibr15-1933719111415546"/>–<xref ref-type="bibr" rid="bibr16-1933719111415546">16</xref>
</sup> After washing with phosphate-buffered saline (PBS)-Tween 0.01%, the secondary antibody (prediluted as supplied in ImmPRESS Reagent Kit, Vector Laboratories, Burlingame, California) was applied for 30 minutes at room temperature. Diaminobenzidine–hydrogen peroxide solution (DAB Kit; Vector Laboratories) was subsequently added for color development. Sections were then counterstained with hematoxylin (Vector Laboratories) and mounted with Clarion mounting medium (Sigma-Aldrich, St. Louis, Missouri). A Leica microscope (Leica Microsystems, Ltd, Wetzlar, Germany) was used to visualize the staining and to photograph the results.</p>
</sec>
<sec id="section7-1933719111415546">
<title>Qualitative Evaluation of Immunohistochemistry</title>
<p>The staining intensity of the tissues was scored on a scale of 0 = <italic>no staining</italic>, 1 = <italic>faint staining</italic>, 2 = <italic>moderate staining</italic>, and 3 = <italic>strong staining</italic>. Each disease and no disease sample (PE, n = 3 and n = 4; ESE n = 4 and n = 4; MSE n = 4 and n = 4, respectively) was analyzed 3 times by 1 investigator, blinded to the identities of the samples, and the results were verified by 2 other observers. The average values from the biological replicates are presented.</p>
</sec>
</sec>
<sec id="section8-1933719111415546">
<title>Results</title>
<sec id="section9-1933719111415546">
<title>Gene Expression: Endometrium in the Absence of Endometriosis</title>
<p>In the transition from the proliferative (E<sub>2</sub> dominant) to early secretory phase (beginning of P<sub>4</sub> action), analysis of endometrial NR/coregulator expression in controls (Table <xref ref-type="table" rid="table2-1933719111415546">2</xref>) revealed increased expression of peroxisome proliferator-activated receptor gamma (<italic>PPARG</italic>), <italic>NOTCH2</italic>, and nuclear coactivator 1 ([<italic>NCOA1</italic>], also known as steroid receptor coactivator 1 [<italic>SRC1</italic>], a histone acetylase [HAT] member), along with decreased expression of retinoic acid receptor alpha (<italic>RARA</italic>) and nuclear receptor subfamily 4, group A (<italic>NR4A1</italic>). In MSE compared to ESE, <italic>RARA</italic> was the only upregulated gene, while downregulation of <italic>HDAC3</italic>, vitamin D receptor (VDR), <italic>ESR1</italic>, cAMP responsive element binding protein (CREB)-binding protein (<italic>CREBBP</italic>), and other genes were observed (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>). In MSE (peak P<sub>4</sub> action on the tissue), compared to PE (E<sub>2</sub> dominant) increased expression of retinoic acid receptor-related orphan receptor A (<italic>RORA</italic>), the aryl hydrocarbon receptor nuclear translocator (<italic>ARNT</italic>), and nuclear corepressor 1 (<italic>NCOR1</italic>), among others, were observed (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>). Decreased expression of <italic>HDAC3</italic>, metastasis-associated protein 1 (<italic>MTA1</italic>, a component of the Dermatomyositis-specific autoantigen (Mi-2)/nucleosome remodeling and deacetylating complex that acts as a potent corepressor of ESR), as well as <italic>ESR1</italic> was observed (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>), Interestingly, THRA, retinoid X receptor gamma (<italic>RXRG</italic>), and the androgen receptor (<italic>AR</italic>) were also downregulated in MSE versus PE (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>).</p>
<table-wrap id="table2-1933719111415546" position="float">
<label>Table 2.</label>
<caption>
<p>Nuclear Receptor and Coregulator Expression in the Endometrium of Women Without Endometriosis</p>
</caption>
<graphic alternate-form-of="table2-1933719111415546" xlink:href="10.1177_1933719111415546-table2.tif"/>
<table>
<thead>
<tr>
<th>Gene</th>
<th align="center">Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Control endometrium: early secretory vs proliferative phase</td>
</tr>
<tr>
<td>
<italic> PPARG</italic>
</td>
<td>4.4</td>
</tr>
<tr>
<td>
<italic> NOTCH2</italic>
</td>
<td>3.0</td>
</tr>
<tr>
<td>
<italic> NCOA1</italic>
</td>
<td>2.8</td>
</tr>
<tr>
<td>
<italic> PPARA</italic>
</td>
<td>1.8</td>
</tr>
<tr>
<td>
<italic> RARA</italic>
</td>
<td>−3.7</td>
</tr>
<tr>
<td>
<italic> NR4A1</italic>
</td>
<td>−6.1</td>
</tr>
<tr>
<td colspan="2">Control endometrium: mid-secretory vs early secretory phase</td>
</tr>
<tr>
<td>
<italic> RARA</italic>
</td>
<td>2.64</td>
</tr>
<tr>
<td>
<italic> HDAC3</italic>
</td>
<td>−1.5</td>
</tr>
<tr>
<td>
<italic> NONO</italic>
</td>
<td>−1.6</td>
</tr>
<tr>
<td>
<italic> CREBBP</italic>
</td>
<td>−1.7</td>
</tr>
<tr>
<td>
<italic> MED12</italic>
</td>
<td>−1.9</td>
</tr>
<tr>
<td>
<italic> VDR</italic>
</td>
<td>−3.4</td>
</tr>
<tr>
<td>
<italic> ESR1</italic>
</td>
<td>−3.6</td>
</tr>
<tr>
<td>
<italic> RXRG</italic>
</td>
<td>−6.7</td>
</tr>
<tr>
<td colspan="2">Control endometrium: mid-secretory vs proliferative phase</td>
</tr>
<tr>
<td>
<italic> RORA</italic>
</td>
<td>3.3</td>
</tr>
<tr>
<td>
<italic> NR1H3</italic>
</td>
<td>2.2</td>
</tr>
<tr>
<td>
<italic> ARNT</italic>
</td>
<td>2.0</td>
</tr>
<tr>
<td>
<italic> MED13</italic>
</td>
<td>1.9</td>
</tr>
<tr>
<td>
<italic> NCOR1</italic>
</td>
<td>1.9</td>
</tr>
<tr>
<td>
<italic> MED24</italic>
</td>
<td>−1.6</td>
</tr>
<tr>
<td>
<italic> MED12</italic>
</td>
<td>−1.6</td>
</tr>
<tr>
<td>
<italic> HDAC3</italic>
</td>
<td>−1.7</td>
</tr>
<tr>
<td>
<italic> MTA1</italic>
</td>
<td>−1.8</td>
</tr>
<tr>
<td>
<italic> THRA</italic>
</td>
<td>−2.3</td>
</tr>
<tr>
<td>
<italic> NR0B2</italic>
</td>
<td>−2.8</td>
</tr>
<tr>
<td>
<italic> RXRG</italic>
</td>
<td>−2.8</td>
</tr>
<tr>
<td>
<italic> ESR1</italic>
</td>
<td>−4.0</td>
</tr>
<tr>
<td>
<italic> AR</italic>
</td>
<td>−4.2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-1933719111415546">
<p>Abbreviations: AR, androgen receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; CREBBP, CREB-binding protein; ESR1, estrogen receptor 1; HDAC3, histone deacetylase 3; MED12, mediator complex subunit 12; MED13, mediator complex subunit 13; MED24, mediator complex subunit 24; MTA1, metastasis-associated 1; NCOA1, nuclear coactivator 1; NCOR1, nuclear receptor corepressor 1; NONO, nou-POU domain containing, octamer-binding; NR0B2, nuclear receptor subfamily 0, group B, member 2; NR1H3, nuclear receptor subfamily 1, group H, member 3; NR4A1, nuclear receptor subfamily 4, group A, member 1; PPARA, peroxisome proliferator-activated receptor alpha; PPARG, peroxisome proliferator-activated receptor gamma; RARA, retinoic acid receptor alpha; RORA, retinoic acid receptor-related orphan receptor A; RXRG, retinoid X receptor gamma; THRA, thyroid hormone receptor alpha.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1933719111415546">
<title>Gene Expression: Endometrium in the Presence of Endometriosis</title>
<p>In the setting of endometriosis, <italic>HDAC1</italic> and <italic>HDAC2</italic>, which interact directly with proteins recruited to steroid hormone receptors and are part of the transcriptional complex, were upregulated in the proliferative (E<sub>2</sub>-dominant) phase, compared to controls without disease, and <italic>MTA2</italic>, a potent ESR corepressor was downregulated (<xref ref-type="table" rid="table3-1933719111415546">Table 3</xref>). In the early secretory phase (beginning of P<sub>4</sub> action and where P<sub>4</sub> resistance is first observed in endometrium of women with severe endometriosis<sup>
<xref ref-type="bibr" rid="bibr12-1933719111415546">12</xref>
</sup>), even higher expression of <italic>HDAC1</italic> and <italic>HDAC2</italic> in endometrium from women with versus without endometriosis was observed, compared to the proliferative phase (<xref ref-type="table" rid="table3-1933719111415546">Table 3</xref>).</p>
<table-wrap id="table3-1933719111415546" position="float">
<label>Table 3.</label>
<caption>
<p>Nuclear Receptor and Coregulator Expression in the Endometrium of Women With Versus Without Endometriosis</p>
</caption>
<graphic alternate-form-of="table3-1933719111415546" xlink:href="10.1177_1933719111415546-table3.tif"/>
<table>
<thead>
<tr>
<th>Gene</th>
<th align="center">Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proliferative phase</td>
<td>
</td>
</tr>
<tr>
<td>
<italic> DDX5</italic>
</td>
<td>7.6</td>
</tr>
<tr>
<td>
<italic> HDAC2</italic>
</td>
<td>4.2</td>
</tr>
<tr>
<td>
<italic> NCOA1</italic>
</td>
<td>3.9</td>
</tr>
<tr>
<td>
<italic> ITGB3PB</italic>
</td>
<td>3.6</td>
</tr>
<tr>
<td>
<italic> COPS2</italic>
</td>
<td>3.3</td>
</tr>
<tr>
<td>
<italic> RBPJ</italic>
</td>
<td>3.2</td>
</tr>
<tr>
<td>
<italic> NCOR1</italic>
</td>
<td>2.9</td>
</tr>
<tr>
<td>
<italic> HDAC1</italic>
</td>
<td>2.8</td>
</tr>
<tr>
<td>
<italic> MED17</italic>
</td>
<td>2.8</td>
</tr>
<tr>
<td>
<italic> MED4</italic>
</td>
<td>2.7</td>
</tr>
<tr>
<td>
<italic> BRD8</italic>
</td>
<td>2.5</td>
</tr>
<tr>
<td>
<italic> MED14</italic>
</td>
<td>2.3</td>
</tr>
<tr>
<td>
<italic> ANRT</italic>
</td>
<td>2.2</td>
</tr>
<tr>
<td>
<italic> NCOA6</italic>
</td>
<td>1.5</td>
</tr>
<tr>
<td>
<italic> THRA</italic>
</td>
<td>−2.7</td>
</tr>
<tr>
<td>
<italic> MTA1</italic>
</td>
<td>−2.8</td>
</tr>
<tr>
<td>
<italic> MED16</italic>
</td>
<td>−3.8</td>
</tr>
<tr>
<td>
<italic> NR4A1</italic>
</td>
<td>−4.7</td>
</tr>
<tr>
<td>
<italic> NR2F6</italic>
</td>
<td>−5.7</td>
</tr>
<tr>
<td colspan="2">Mid-secretory phase</td>
</tr>
<tr>
<td>
<italic> RARB</italic>
</td>
<td>1.7</td>
</tr>
<tr>
<td colspan="2">Early secretory phase</td>
</tr>
<tr>
<td>
<italic> DDX5</italic>
</td>
<td>11.3</td>
</tr>
<tr>
<td>
<italic> HDAC2</italic>
</td>
<td>6.3</td>
</tr>
<tr>
<td>
<italic> NCOA1</italic>
</td>
<td>5.9</td>
</tr>
<tr>
<td>
<italic> ITGB3PB</italic>
</td>
<td>5.4</td>
</tr>
<tr>
<td>
<italic> NR2C2</italic>
</td>
<td>5.3</td>
</tr>
<tr>
<td>
<italic> COPS2</italic>
</td>
<td>4.9</td>
</tr>
<tr>
<td>
<italic> RBPJ</italic>
</td>
<td>4.8</td>
</tr>
<tr>
<td>
<italic> MED1</italic>
</td>
<td>4.6</td>
</tr>
<tr>
<td>
<italic> NR2C1</italic>
</td>
<td>4.4</td>
</tr>
<tr>
<td>
<italic> NCOR1</italic>
</td>
<td>4.3</td>
</tr>
<tr>
<td>
<italic> HDAC1</italic>
</td>
<td>4.2</td>
</tr>
<tr>
<td>
<italic> MED17</italic>
</td>
<td>4.2</td>
</tr>
<tr>
<td>
<italic> MED4</italic>
</td>
<td>4.1</td>
</tr>
<tr>
<td>
<italic> BRD8</italic>
</td>
<td>3.8</td>
</tr>
<tr>
<td>
<italic> NCOA3</italic>
</td>
<td>3.4</td>
</tr>
<tr>
<td>
<italic> MED14</italic>
</td>
<td>3.4</td>
</tr>
<tr>
<td>
<italic> ARNT</italic>
</td>
<td>3.4</td>
</tr>
<tr>
<td>
<italic> NR3C2</italic>
</td>
<td>3.1</td>
</tr>
<tr>
<td>
<italic> NR3C1</italic>
</td>
<td>3.1</td>
</tr>
<tr>
<td>
<italic> NR1D2</italic>
</td>
<td>2.9</td>
</tr>
<tr>
<td>
<italic> NCOA6</italic>
</td>
<td>2.2</td>
</tr>
<tr>
<td>
<italic> NR2F2</italic>
</td>
<td>1.7</td>
</tr>
<tr>
<td>
<italic> MED16</italic>
</td>
<td>−2.6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-1933719111415546">
<p>Abbreviations: BRD8, bromodomain containing 8; COPS2, COP9 constitutive photomorphogenic homolog subunit 2 (arabidopsis); DDX5, DEAD (Asp-Glu Ala-Asp) box polypeptide 5; HDAC1, histone deacetylase 1; HDAC2, histone deacetylase 2; ITGB3BP, integrin beta 3 binding protein (beta3-endonexin) MED1, mediator complex subunit 1; MED14, mediator complex subunit 14; MED16, mediator complex subunit 16; MED17, mediator complex subunit 17 MED17, mediator complex subunit 17; MED4, mediator complex subunit 4; NCOA3, nuclear receptor coactivator 3; NCOA6, nuclear receptor coactivator 6 NR1D2, nuclear receptor subfamily 1, group D, member 2; NR2C1, nuclear receptor subfamily 2, group C, member 1; NR2C2, nuclear receptor subfamily 2 group C member 2; NR2F2, nuclear receptor subfamily 2, group F, member 2; NR2F6, nuclear receptor subfamily 2, group F, member 1; NR3C1, nuclear receptor subfamily 3, group C, member 1; NR3C2, nuclear receptor subfamily 3, group C, member 2; NR4A1, nuclear receptor subfamily 4, group A, member 1; RBPJ, recombination signal binding protein for immunoglobulin kappa J region.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Upregulation of a number of other transcription factors was observed, including <italic>NCOA1</italic>, <italic>NCOR1</italic>, and <italic>NCOA3</italic> (which recruits p300/CBP (C-terminal Src kinase (Csk)-binding protein) -associated factor and CREB-binding protein), and recombination signal-binding protein for Ig kappa J region (<italic>RBPJ</italic>, a DNA-binding protein that interacts with the Notch intracellular domain to activate transcription of genes that inhibit cell differentiation).<sup>
<xref ref-type="bibr" rid="bibr17-1933719111415546">17</xref>,<xref ref-type="bibr" rid="bibr18-1933719111415546">18</xref>
</sup>
</p>
<p>Overall, of the 3 phases of the menstrual cycle investigated herein, the early secretory phase had the highest number of statistically significantly upregulated genes in endometrium from women with versus without disease (Table <xref ref-type="table" rid="table3-1933719111415546">3</xref>). The most highly upregulated gene in the proliferative and early secretory phases was DDX5, a transcriptional repressor that associates with HDAC1.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111415546">19</xref>
</sup> In the mid-secretory phase, only 1 gene, <italic>RARB</italic>, was upregulated in disease versus controls (Table <xref ref-type="table" rid="table3-1933719111415546">3</xref>).</p>
</sec>
<sec id="section11-1933719111415546">
<title>Ingenuity Pathway Analysis</title>
<sec id="section12-1933719111415546">
<title>Endometrium in the absence of endometriosis</title>
<p>In the transition from the proliferative to the early secretory phase, the cellular development/embryonic development/gene expression network was upregulated, based on PPARA, PPARG, and NCOA1 expression involved in the PPAR-signaling pathway (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>). In the early to mid-secretory transition, Ingenuity Pathway Analysis (IPA) analysis revealed the drug metabolism/embryonic development/lipid metabolism network affected, with upregulation of retinoic acid-mediated apoptosis signaling, based on the upregulation of RARA and downregulation of RXRG (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>). In the comparison of the mid-secretory phase to the proliferative phase, the gene expression/cell signaling/nutritional disease network was downregulated, based on the downregulation of THRA and ESR1 in the estrogen receptor-signaling pathway and the downregulation of HDAC3 and upregulation of NCOR1 in the thyroid hormone (TR)/RXR pathway (<xref ref-type="table" rid="table2-1933719111415546">Table 2</xref>). For a more comprehensive list of networks and pathways revealed by IPA, see supplemental data (Supplement <xref ref-type="table" rid="table1-1933719111415546">Tables 1</xref>-<xref ref-type="table" rid="table3-1933719111415546">3</xref>).</p>
</sec>
<sec id="section13-1933719111415546">
<title>Endometrium in the setting of endometriosis</title>
<p>IPA identified DNA methylation and transcriptional repression signaling as the most affected pathway in endometrium in women with versus without disease, regardless of the cycle phase.</p>
<p>In the proliferative phase, gene expression/cell signaling was the first ranked affected network, and DNA methylation and transcriptional repression signaling were the first ranked canonical pathway to be upregulated in endometrium from women with versus without disease. The genes involved in these processes were <italic>HDAC1</italic>, <italic>HDAC2</italic>, and <italic>MTA1</italic> (<xref ref-type="table" rid="table3-1933719111415546">Table 3</xref>). The THR/RXR pathway was affected by the downregulation of <italic>THRA</italic> expression in the proliferative phase in endometriosis, compared to control samples (<xref ref-type="table" rid="table3-1933719111415546">Table 3</xref>). In disease versus no disease in the early secretory phase, IPA analysis revealed THRA and VDR pathway activation, by the upregulation of <italic>NCOA1</italic>, <italic>NCOA3</italic>, <italic>NCOR1</italic>, and mediator complex subunit 1 (<italic>MED1</italic>) gene expression (<xref ref-type="table" rid="table3-1933719111415546">Table 3</xref>). A more comprehensive list of networks and pathways revealed by IPA is provided in the supplemental data (Supplement <xref ref-type="table" rid="table4-1933719111415546">Tables 4</xref>-6).</p>
<table-wrap id="table4-1933719111415546" position="float">
<label>Table 4.</label>
<caption>
<p>Nuclear Immunostaining Intensities of DDX5, HDAC1, and THRA in Cycling Endometrium of Women With and Without Disease<sup><xref ref-type="table-fn" rid="table-fn13-1933719111415546">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-1933719111415546" xlink:href="10.1177_1933719111415546-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">Disease PE</th>
<th align="center">No Disease PE</th>
<th align="center">Disease ESE</th>
<th align="center">No Disease ESE</th>
<th align="center">Disease MSE</th>
<th align="center">No Disease MSE</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7">DDX5</td>
</tr>
<tr>
<td> Luminal epithelium<sup><xref ref-type="table-fn" rid="table-fn14-1933719111415546">b</xref></sup>
</td>
<td>2.75 ± 0.25 </td>
<td>2.25 ± 0.25</td>
<td align="center">NA</td>
<td>3.00 ± 0.00</td>
<td>2.00 ± 0.00</td>
<td align="center">NA</td>
</tr>
<tr>
<td> Glandular epithelium</td>
<td>2.50 ± 0.00 </td>
<td>2.00 ± 0.29</td>
<td>2.38 ± 0.31</td>
<td>1.63 ± 0.38</td>
<td>2.75 ± 0.25</td>
<td>1.75 ± 0.14</td>
</tr>
<tr>
<td> Stromal cells</td>
<td>1.83 ± 0.17</td>
<td>2.00 ± 0.29</td>
<td>2.00 ± 0.29</td>
<td>2.13 ± 0.24</td>
<td>2.25 ± 0.32</td>
<td>1.75 ± 0.14</td>
</tr>
<tr>
<td colspan="7">HDAC1</td>
</tr>
<tr>
<td> Luminal epithelium<sup><xref ref-type="table-fn" rid="table-fn14-1933719111415546">b</xref></sup>
</td>
<td align="center">NA</td>
<td>2.00 ± 1.00</td>
<td>1.17 ± 0.93</td>
<td>0.83 ± 0.60</td>
<td align="center">NA</td>
<td align="center">NA</td>
</tr>
<tr>
<td> Glandular epithelium</td>
<td>2.67 ± 0.17</td>
<td>2.67 ± 0.33</td>
<td>2.25 ± 0.43</td>
<td>2.13 ± 0.38</td>
<td>2.13 ± 0.13</td>
<td>2.13 ± 0.24</td>
</tr>
<tr>
<td> Stromal cells</td>
<td>2.50 ± 0.00</td>
<td>2.83 ± 0.17</td>
<td>2.63 ± 0.38</td>
<td>2.25 ± 0.60</td>
<td>1.63 ± 0.43</td>
<td>1.38 ± 0.52</td>
</tr>
<tr>
<td colspan="7">THRA</td>
</tr>
<tr>
<td> Luminal epithelium<sup><xref ref-type="table-fn" rid="table-fn14-1933719111415546">b</xref></sup>
</td>
<td>2.50 ± 0.29</td>
<td align="center">NA</td>
<td>2.00 ± 0.50</td>
<td>0.25 ± 0.14</td>
<td>1.17 ± 0.17</td>
<td align="center">NA</td>
</tr>
<tr>
<td> Glandular epithelium</td>
<td>2.67 ± 0.33 </td>
<td>3.00 ± 0.00</td>
<td>2.13 ± 0.24</td>
<td>1.50 ± 0.58</td>
<td>1.63 ± 0.24</td>
<td>2.17 ± 0.44</td>
</tr>
<tr>
<td> Stromal cells</td>
<td>1.67 ± 0.60</td>
<td>2.17 ± 0.83</td>
<td>1.88 ± 0.24</td>
<td>1.75 ± 0.48</td>
<td>1.00 ± 0.29</td>
<td>1.67 ± 0.73</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-1933719111415546">
<p>Abbreviations: NA, not available; DDX5, DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; HDAC1, histone deacetylase 1; THRA, thyroid hormone receptor alpha; RXRG, retinoid X receptor gamma; SEM standard error of the mean.</p>
</fn>
<fn id="table-fn13-1933719111415546">
<p>
<sup>a</sup> Values represent mean immunostaining intensities ± SEM.</p>
</fn>
<fn id="table-fn14-1933719111415546">
<p>
<sup>b</sup> Some paraffin sections did not contain luminal epithelium.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section14-1933719111415546">
<title>Protein Validation by Immunohistochemistry</title>
<p>To validate the PCR array results and determine cellular localization of corresponding proteins, immunohistochemistry of the most highly upregulated genes (<italic>DDX5</italic> and <italic>HDAC1</italic>), as well as THRA proteins was performed. Average staining intensities are presented in <xref ref-type="table" rid="table4-1933719111415546">Table 4</xref>.</p>
</sec>
<sec id="section15-1933719111415546">
<title>DDX5 protein</title>
<p>DDX5 immunostaining was observed in the nuclei of luminal and glandular epithelium and stromal cells. In PE from women with endometriosis variable immunoreactivity was observed in glandular epithelium (<xref ref-type="fig" rid="fig1-1933719111415546">Figure 1A</xref>). Controls had more consistent expression of DDX5 (<xref ref-type="fig" rid="fig1-1933719111415546">Figure 1B</xref>) but with similar intensities as the disease samples. In the early secretory phase, stronger immunoreactivity was observed in tissue from women with endometriosis, especially in the glandular and luminal epithelia (<xref ref-type="fig" rid="fig1-1933719111415546">Figure 1C</xref> and D). Stromal cells had variable expression in samples from women with and without disease. Equal intensities of immunoreactivity were observed in the mid-secretory phase of women with and without the disease (data not shown). The increase of DDX5 protein observed in the disease samples in the early secretory phase is consistent with the upregulation of DDX5 gene expression in this phase of the cycle.</p>
<fig id="fig1-1933719111415546" position="float">
<label>Figure 1.</label>
<caption>
<p>Results of immunostaining for DEAD box polypeptide 5 (DDX5) in disease and no disease endometrium. Immunoreactivity of DDX5 was observed equally in the proliferative phase of both disease (A) and no disease (B) endometrium. Number of positively stained glandular epithelial cells increased in early secretory phase of disease (C), and decreased in no disease (D). Human placenta was used as positive control (E) and nonimmune isotype as negative control (F). Magnification, ×20. Scale bar, 40 µm.</p>
</caption>
<graphic alternate-form-of="fig1-1933719111415546" xlink:href="10.1177_1933719111415546-fig1.tif"/>
</fig>
</sec>
<sec id="section16-1933719111415546">
<title>HDAC1 protein</title>
<p>Nuclear immunostaining of HDAC1 was observed in luminal and glandular epithelium and stromal cells. In the proliferative phase, equal intensities were observed in glandular epithelium and stromal cells (data not shown). Stronger HDAC1 immunoreactivity was observed in the early secretory phase, especially in the glandular epithelium of disease samples (<xref ref-type="fig" rid="fig2-1933719111415546">Figure 2A</xref> and B). In the mid-secretory phase, similar HDAC1 immunoreactivity was observed in stromal cells; whereas glandular epithelium had sporadic immunoreactivity regardless of the presence of disease (data not shown). While similar intensities in the proliferative phase are in contrast with the gene expression results of HDAC1, stronger immunoreactivity observed in glandular epithelium of disease samples in the early secretory phase is consistent with the PCR array analysis. </p>
<fig id="fig2-1933719111415546" position="float">
<label>Figure 2.</label>
<caption>
<p>Results of immunostaining for histone deacetylase 1 (HDAC1) in disease and no disease endometrium. In the early secretory phase, stronger immunoreactivity was observed in glandular epithelium of disease samples (A) compared to no disease samples (B). Human placenta was used as positive control (C) and nonimmune isotype as negative control (D). Magnification, ×20. Scale bar, 40 µm.</p>
</caption>
<graphic alternate-form-of="fig2-1933719111415546" xlink:href="10.1177_1933719111415546-fig2.tif"/>
</fig>
</sec>
<sec id="section17-1933719111415546">
<title>THRA protein</title>
<p>In glandular epithelium, there was stronger THRA protein immunoreactivity in control samples in the PE and MSE phases, compared to ESE (<xref ref-type="fig" rid="fig3-1933719111415546">Figure 3B</xref> and D, respectively), confirming earlier findings.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111415546">20</xref>
</sup> In endometriosis samples, THRA immunoreactivity was the highest in glandular epithelium of the proliferative phase and lowest in the mid-secretory phase (<xref ref-type="fig" rid="fig3-1933719111415546">Figure 3A</xref> and E, respectively). Stronger immunostaining was observed in the PE phase of the control samples, and no significant differences were observed in the ESE phase between endometriosis and control samples (<xref ref-type="fig" rid="fig3-1933719111415546">Figure 3C</xref> and D). Luminal epithelium had variable protein expression throughout all phases of the cycle in disease and no disease. Stronger immunoreactivity in the control samples compared to the disease samples is consistent with the downregulation of THRA gene expression in the proliferative phase of disease samples and activation of TR/RXR pathway in the mid-secretory versus proliferative phase, identified by IPA analysis.</p>
<fig id="fig3-1933719111415546" position="float">
<label>Figure 3.</label>
<caption>
<p>Results of immunostaining for thyroid hormone receptor alpha (THRA) protein in disease and no disease endometrium. In the proliferative phase, THRA protein expression was localized mainly to the glandular epithelium of both disease (A) and no disease (B) samples, with stronger expression in no disease samples. In the mid-secretory phase, stronger expression was observed in the glandular epithelium of no disease samples (D) compared to disease (C) samples. Human placenta was used as positive control (E) and nonimmune isotype as negative control (F). Magnification, ×20. Scale bar, 40 µm.</p>
</caption>
<graphic alternate-form-of="fig3-1933719111415546" xlink:href="10.1177_1933719111415546-fig3.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec id="section18-1933719111415546">
<title>Discussion</title>
<sec id="section19-1933719111415546">
<title>Nuclear Receptors and Coregulators in Human Endometrium Without Endometriosis</title>
<p>The current study underscores the involvement of key signaling pathways of NRs and coregulators and other transcription factors in human endometrium during the P<sub>4</sub>-dominant phase of the menstrual cycle, as well as abnormalities in some of these in endometrium from women with endometriosis.</p>

<sec id="section20-1933719111415546">
<title>ESR, AR, NCOAs, NCORs</title>
<p>In endometrium, E<sub>2</sub> induces cell proliferation; whereas P<sub>4</sub> inhibits estrogen action and induces glandular and stromal cell differentiation in the secretory phase of the cycle.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111415546">21</xref>
</sup> Steroid receptors such as ESR, AR, and PGR recruit NCORs and NCOAs to mediate gene expression.<sup>
<xref ref-type="bibr" rid="bibr22-1933719111415546">22</xref>
</sup> Downregulation of <italic>ESR</italic> and <italic>AR</italic> in secretory versus PE of women without endometriosis, reported herein, is consistent with the findings of others.<sup>
<xref ref-type="bibr" rid="bibr22-1933719111415546">22</xref>
</sup> However, there are conflicting data regarding NCOA1 and NCOR1 in human endometrium. Some studies have found that their messenger RNA (mRNA) levels are not cycle dependent<sup>
<xref ref-type="bibr" rid="bibr22-1933719111415546">22</xref>
</sup>; whereas others found lower expression of NCOA1 and NCOR1 proteins in the secretory, compared to the proliferative, phase.<sup>
<xref ref-type="bibr" rid="bibr23-1933719111415546">23</xref>
</sup> Our results demonstrate an increase of <italic>NCOA1</italic> mRNA in ESE and an increase of <italic>NCOR1</italic> in MSE, suggesting roles for them in steroid hormone action in endometrium during the P<sub>4</sub>-dominant phase of the cycle. Nuclear coactivator 1 interacts with ESR1 and PGR in a ligand-dependent manner to enhance hormone-dependent transcriptional activities.<sup>
<xref ref-type="bibr" rid="bibr24-1933719111415546">24</xref>
</sup> We speculate that the NCOA pathway may play a general role in facilitating P<sub>4</sub> action in the ESE.</p>
</sec>
<sec id="section21-1933719111415546">
<title>Thyroid hormone</title>
<p>The thyroid hormone-signaling pathway consists of many proteins that regulate thyroid hormone synthesis and activation, as well as activation of gene transcription by NRs. Only recently has this family been identified in human endometrium, suggesting participation in endometrial function.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111415546">20</xref>,<xref ref-type="bibr" rid="bibr25-1933719111415546">25</xref>
</sup> We confirmed herein earlier findings of THRA protein expression in human endometrium across the cycle from women without endometriosis.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111415546">20</xref>
</sup> Our findings and those of Aghajanova et al<sup>
<xref ref-type="bibr" rid="bibr20-1933719111415546">20</xref>
</sup> are in contrast to the findings using microarray analysis, by Catalano et al,<sup>
<xref ref-type="bibr" rid="bibr25-1933719111415546">25</xref>
</sup> of <italic>THRA1</italic> and <italic>THRB1</italic> mRNA expression significantly increased from the proliferative to the secretory phase. The reasons for the differences are unclear, although they may be due to the different methodologies used.</p>
</sec>
<sec id="section22-1933719111415546">
<title>Chromatin-remodeling mediators</title>
<p>Histone deacetylases, HATs, and DNA methyltransferases (DNMTs) have been minimally investigated in human endometrium. Class I HDACs, HDAC1, 2, and 3 play an important role in steroid hormone-dependent gene expression by directly interacting with steroid hormone receptor proteins and other members of the transcriptional complex after ligand binding.<sup>
<xref ref-type="bibr" rid="bibr26-1933719111415546">26</xref>
</sup> Treatment of endometrial adenocarcinoma cells with the HDAC inhibitor, valproic acid, blocks estrogen-induced cellular proliferation, suggesting a potential link between endometrial proliferation and histone acetylation.<sup>
<xref ref-type="bibr" rid="bibr27-1933719111415546">27</xref>
</sup> Krusche et al<sup>
<xref ref-type="bibr" rid="bibr28-1933719111415546">28</xref>
</sup> found that HDAC 1, 2, and 3 mRNAs were constitutively expressed in human endometrium, while the proteins were expressed variably with a trend toward higher HDAC2 in the secretory phase and a reduction of HDAC3 in surface epithelium. In our transcriptome study of human endometrium across the menstrual cycle in normo-ovulatory women without endometriosis, we found about a 2-fold significant downregulation of <italic>HDAC2</italic>, Histone H2A histone family, member V (H2aV), and <italic>DNMT 1</italic>, <italic>3A</italic>, and <italic>3B</italic> in the mid-secretory phase (peak P<sub>4</sub>) compared to the proliferative phase (peak E<sub>2</sub>).<sup>
<xref ref-type="bibr" rid="bibr29-1933719111415546">29</xref>
</sup> Recently, preliminary data were presented<sup>
<xref ref-type="bibr" rid="bibr30-1933719111415546">30</xref>
</sup> on the total acetylation (ac) level in normal endometrium of specific lysines of histones 2A, 2B, 3, and 4, by Western blotting. A significant progressive decline of H2AK5ac was found across the proliferative phase, a decline in H3K9ac between the early and late proliferative phases, and a decline in H4K8ac progressively across the proliferative phase and a peak in the mid-secretory phase. In contrast, there were no significant differences in H2BK12ac, H3K14/18ac, or H4K5ac across the cycle,<sup>
<xref ref-type="bibr" rid="bibr30-1933719111415546">30</xref>
</sup> suggesting selectivity to the acetylome changes. In the current study, we observed a decrease of <italic>HDAC3</italic> mRNA in the mid-secretory phase of the menstrual cycle compared to the proliferative phase, which correlates well with the immunostaining results of HDAC3 conducted by Krusche et al.<sup>
<xref ref-type="bibr" rid="bibr28-1933719111415546">28</xref>
</sup> Furthermore, similar results were observed in the immunostaining of HDAC1 in stromal cells in the cycling endometrium, herein, and in the study by Krusche et al.<sup>
<xref ref-type="bibr" rid="bibr28-1933719111415546">28</xref>
</sup> Importantly, overall these findings support a role for chromatin remodeling in different hormonal milieu across the menstrual cycle in human endometrium.</p>
</sec>
</sec>
<sec id="section23-1933719111415546">
<title>Endometrium in the Setting of Endometriosis</title>
<p>The results herein demonstrate the dysregulation of a number of NRs, coregulators, and signaling pathways in endometrium in women with endometriosis versus those without disease that have relevance to the pathophysiology of the disorder and are potential targets for therapy.</p>
<sec id="section24-1933719111415546">
<title>NCORs and NCOAs</title>
<p>Steroid receptor cofactors play an important role in steroid receptor signaling. A recent study found higher NCOR expression in the epithelium of ovarian endometriomas in the secretory phase, compared to normal eutopic endometrium,<sup>
<xref ref-type="bibr" rid="bibr31-1933719111415546">31</xref>
</sup> and NCOR expression is higher in endometrial hyperplasia compared to normal and neoplastic endometrial cells.<sup>
<xref ref-type="bibr" rid="bibr32-1933719111415546">32</xref>
</sup> Herein, we found higher levels of <italic>NCOR1</italic> in secretory phase eutopic endometrium of women with versus without disease, suggesting a role for this coregulator in repressing P<sub>4</sub> action and increased E<sub>2</sub> signaling in the setting of endometriosis. Nuclear corepressor represses transcription by recruiting HDACs, and overexpression of <italic>NCOR </italic>represses the activity of ligand-bound PGR and ESR.<sup>
<xref ref-type="bibr" rid="bibr33-1933719111415546">33</xref>
<xref ref-type="bibr" rid="bibr34-1933719111415546"/>–<xref ref-type="bibr" rid="bibr35-1933719111415546">35</xref>
</sup> In the setting of endometriosis, NCOR most likely downregulates genes targeted by P<sub>4</sub>. This correlates to the findings in the baboon model of endometriosis, where PGRA immunolocalization in glandular epithelial cells was observed to decrease, while PGRB levels remained unchanged in the eutopic endometrium.<sup>
<xref ref-type="bibr" rid="bibr36-1933719111415546">36</xref>
</sup> No difference in PGRA or PGRB immunoreactivity was observed in stromal cells; however, the ability of these cells to respond to PGR hormone and cyclic adenosine monophosphate (cAMP) stimulation is diminished.<sup>
<xref ref-type="bibr" rid="bibr36-1933719111415546">36</xref>
</sup> Jackson et al,<sup>
<xref ref-type="bibr" rid="bibr36-1933719111415546">36</xref>
</sup> observed a decrease of a chaperone immunophilin, 52 kDa FK506 binding protein (FKBP52), which regulates P<sub>4</sub> action. Furthermore, a decrease of <italic>HIC5</italic> expression in stromal cells from eutopic endometrium of endometriosis patients reduces PGR signaling.<sup>
<xref ref-type="bibr" rid="bibr11-1933719111415546">11</xref>
</sup> Overall, the observed decrease of P<sub>4</sub> response could be attributed to the effects of the NCORs or PGR chaperones. Herein, we observed no significant changes in <italic>PGR</italic> mRNA levels, which may suggest that the NCOAs and NCORs affect the functional activity of PGR in the regulation of target genes and not expression per se of PGR in the setting of endometriosis.</p>
<p>The NCOA family members enhance the transcriptional activity of various NRs, including ESR and PGR.<sup>
<xref ref-type="bibr" rid="bibr37-1933719111415546">37</xref>
</sup> Interestingly, in <italic>NCOA1 </italic>null mice, endometrial stromal cell decidualization is compromised in response to E<sub>2</sub> and P<sub>4</sub>.<sup>
<xref ref-type="bibr" rid="bibr38-1933719111415546">38</xref>
</sup> Herein we found upregulation of <italic>NCOA1</italic> in endometrium from women with endometriosis compared to no disease. We speculate that NCOA1 and NCOR1 are important players, competing for binding to ESR and PGR for transcriptional activation and repression—resulting in P<sub>4</sub> resistance and persistence of the proliferative phenotype observed in endometrium from women with endometriosis.<sup>
<xref ref-type="bibr" rid="bibr12-1933719111415546">12</xref>
</sup> The functional role of NOCA1 in endometriosis warrants further investigation.</p>
</sec>
<sec id="section25-1933719111415546">
<title>Thyroid hormone</title>
<p>Since thyroid hormone action in endometrium may be P<sub>4</sub> dependent,<sup>
<xref ref-type="bibr" rid="bibr20-1933719111415546">20</xref>,<xref ref-type="bibr" rid="bibr25-1933719111415546">25</xref>
</sup> decreased expression of THRA in women with endometriosis may reflect P<sub>4</sub> resistance in this tissue in the setting of disease. Thyroid hormone receptors (THRA and THRB) mediate T3 inhibitory effects on ras/mitogen-activated protein kinase (MAPK)-mediated proliferation in neuroblastoma cells and block induction of cyclin D1 expression.<sup>
<xref ref-type="bibr" rid="bibr39-1933719111415546">39</xref>
</sup> Whether THRs are involved in the observed persistent cyclin D1 expression in endometrial cells from women with endometriosis warrants further investigation.<sup>
<xref ref-type="bibr" rid="bibr40-1933719111415546">40</xref>
</sup>
</p>
</sec>
<sec id="section26-1933719111415546">
<title>DDX5 and chromatin remodeling mediators</title>
<p>The most regulated canonical pathway in eutopic endometrium of women with endometriosis compared to controls was DNA methylation and transcriptional repression signaling involving gene and protein upregulation of DDX5 and HDAC1 in the early secretory phase. DDX5, also known as nuclear protein 68, is a member of the DEAD-box family of RNA helicases.<sup>
<xref ref-type="bibr" rid="bibr41-1933719111415546">41</xref>
</sup> Its functions include pre-mRNA splicing, ATPase and helicase activity, and RNA degradation and export.<sup>
<xref ref-type="bibr" rid="bibr41-1933719111415546">41</xref>,<xref ref-type="bibr" rid="bibr42-1933719111415546">42</xref>
</sup> It functions as a transcriptional regulator, especially as a coactivator for ERα<sup>
<xref ref-type="bibr" rid="bibr43-1933719111415546">43</xref>
</sup> and AR.<sup>
<xref ref-type="bibr" rid="bibr44-1933719111415546">44</xref>
</sup> In the context of its function as a coactivator, DDX5 may enhance E<sub>2</sub> action in the endometrium of women with endometriosis. However, DDX5 also acts as a repressor of transcription in a promoter-specific manner<sup>
<xref ref-type="bibr" rid="bibr19-1933719111415546">19</xref>
</sup> and interacts with HDAC1 to promote transcriptional repression.<sup>
<xref ref-type="bibr" rid="bibr41-1933719111415546">41</xref>,<xref ref-type="bibr" rid="bibr45-1933719111415546">45</xref>
<xref ref-type="bibr" rid="bibr46-1933719111415546"/>–<xref ref-type="bibr" rid="bibr47-1933719111415546">47</xref>
</sup> This hypothesis is supported by the results from both the PCR array and immunohistochemistry, due to the similar <italic>HDAC1</italic> and <italic>DDX5</italic> gene and protein expression observed herein. It is important to note that both DDX5 and HDAC1 increased equivalently and in parallel in the proliferative to the early secretory transition, strengthening this conclusion. Histone deacetylation, along with DNA methylation, generates a feedback loop to promote long-term transcriptional repression,<sup>
<xref ref-type="bibr" rid="bibr3-1933719111415546">3</xref>
</sup> and thus upregulation of <italic>HDAC1</italic>, <italic>HDAC2</italic>, and <italic>DDX5</italic> genes in endometriosis in the proliferative and early secretory phases of the menstrual cycle could in fact promote DNA methylation and in turn transcriptional repression of associated genes leading to endometrial dysfunction. These findings support the suggestion of endometriosis as an epigenetic disorder,<sup>
<xref ref-type="bibr" rid="bibr48-1933719111415546">48</xref>
</sup> with multiple sites of gene transcriptional regulation by epigenetic modifications altering cellular function in the setting of disease.</p>
</sec>
<sec id="section27-1933719111415546">
<title>Summary</title>
<p>Steroid hormones impart their ultimate effects through their NRs, which interact with chromatin and initiate diverse transcriptional programs. The genomic localization and functions of these receptors crucially depend on the local epigenetic state of their binding sites, and, in turn, transcription factors can induce chromatin remodeling and modifications. Both E<sub>2</sub> and P<sub>4</sub> thus have intricate interactions with the epigenome of targeted cells. Enforcing these considerations, epigenetic alterations have been linked directly to endometriosis<sup>
<xref ref-type="bibr" rid="bibr48-1933719111415546">48</xref>
</sup> and associated reduced fertility.<sup>
<xref ref-type="bibr" rid="bibr49-1933719111415546">49</xref>
</sup> The present study demonstrates dysregulation of signaling, chromatin remodeling, and gene expression regulatory pathways in eutopic endometrium of women with endometriosis, with the most profound dysregulation occurring within the proliferative and early secretory phases of the menstrual cycle, where the majority of those genes are dysregulated, especially in the early secretory phase. This is in striking parallel to our previous findings using gene expression analysis that demonstrated a blunted proliferative-to-secretory transition in early secretory phase endometrium.<sup>
<xref ref-type="bibr" rid="bibr12-1933719111415546">12</xref>
</sup> These and data from others<sup>
<xref ref-type="bibr" rid="bibr7-1933719111415546">7</xref>
</sup> have led to the conclusion of P<sub>4</sub> resistance in the endometrium of women with endometriosis. Overall, the data support the involvement of the epigenome and chromatin remodeling in the steroid hormone response of normal endometrium throughout the cycle and also in abnormalities in the endometrium of women with endometriosis. These findings are significant in understanding steroid hormone action in endometriosis due to the coupling of the players in chromatin remodeling and gene transcription and silencing and underscoring the relevance of epigenetics in endometriosis, warranting further studies.</p>
</sec>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Dr. David Erikson for assistance during manuscript preparation.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719111415546">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719111415546">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the <italic>Eunice Kennedy Shriver</italic> National Institute of Child Health and Human Development (NICHD)/NIH through cooperative agreement U54HD055764-04 as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research (LCG).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719111415546">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auboeuf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dowhan</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Dutertre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Berget</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts</article-title>. <source>Mol Cell Biol</source>. <year>2005</year>;<volume>25</volume>(<issue>13</issue>):<fpage>5307</fpage>–<lpage>5316</lpage>.</citation>
</ref>
<ref id="bibr2-1933719111415546">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzpatrick</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>CB</given-names>
</name>
</person-group>. <article-title>Methylation and demethylation in the regulation of genes, cells, and responses in the immune system</article-title>. <source>Clin Immunol</source>. <year>2003</year>;<volume>109</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr3-1933719111415546">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuks</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>DNA methylation and histone modifications: teaming up to silence genes</article-title>. <source>Curr Opin Genet Dev</source>. <year>2005</year>;<volume>15</volume>(<issue>5</issue>):<fpage>490</fpage>–<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr4-1933719111415546">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giudice</surname>
<given-names>LC.</given-names>
</name>
</person-group>
<article-title>Clinical practice. Endometriosis</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>(<issue>25</issue>):<fpage>2389</fpage>–<lpage>2398</lpage>.</citation>
</ref>
<ref id="bibr5-1933719111415546">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eskenazi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Epidemiology of endometriosis</article-title>. <source>Obstet Gynecol Clin North Am</source>. <year>1997</year>;<volume>24</volume>(<issue>2</issue>):<fpage>235</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr6-1933719111415546">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bulun</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>Endometriosis</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>3</issue>):<fpage>268</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr7-1933719111415546">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghajanova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Velarde</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>Altered gene expression profiling in endometrium: evidence for progesterone resistance</article-title>. <source>Semin Reprod Med</source>. <year>2010</year>;<volume>28</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr8-1933719111415546">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bain</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Heneghan</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Connaghan-Jones</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>MT</given-names>
</name>
</person-group>. <article-title>Nuclear receptor structure: implications for function</article-title>. <source>Annu Rev Physiol</source>. <year>2007</year>;<volume>69</volume>:<fpage>201</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr9-1933719111415546">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bulun</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Progesterone resistance in endometriosis: link to failure to metabolize estradiol</article-title>. <source>Mol Cell Endocrinol</source>. <year>2006</year>;<volume>248</volume>(<issue>1-2</issue>):<fpage>94</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr10-1933719111415546">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Strawn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Basir</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Halverson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>SW</given-names>
</name>
</person-group>. <article-title>Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis</article-title>. <source>Epigenetics</source>. <year>2006</year>;<volume>1</volume>(<issue>2</issue>):<fpage>106</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr11-1933719111415546">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghajanova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Velarde</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis</article-title>. <source>Endocrinology</source>. <year>2009</year>;<volume>150</volume>(<issue>8</issue>):<fpage>3863</fpage>–<lpage>3870</lpage>.</citation>
</ref>
<ref id="bibr12-1933719111415546">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burney</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Talbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>AE</given-names>
</name>
<etal/>
</person-group> <article-title>Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis</article-title>. <source>Endocrinology</source>. <year>2007</year>;<volume>148</volume>(<issue>8</issue>):<fpage>3814</fpage>–<lpage>3826</lpage>.</citation>
</ref>
<ref id="bibr13-1933719111415546">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghajanova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>Molecular evidence for differences in endometrium in severe versus mild endometriosis</article-title>. <source>Reprod Sci</source>. <year>2011</year>;<volume>18</volume>(<issue>3</issue>):<fpage>229</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr14-1933719111415546">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Histone deacetylase 3 binds to and regulates the GCMa transcription factor</article-title>. <source>Nucleic Acids Res</source>. <year>2006</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1459</fpage>–<lpage>1469</lpage>.</citation>
</ref>
<ref id="bibr15-1933719111415546">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Szilak</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>GI</given-names>
</name>
<name>
<surname>DeGroot</surname>
<given-names>LJ</given-names>
</name>
</person-group>. <article-title>Characterization of a thyroid hormone receptor expressed in human kidney and other tissues</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1988</year>;<volume>85</volume>(<issue>8</issue>):<fpage>2781</fpage>–<lpage>2785</lpage>.</citation>
</ref>
<ref id="bibr16-1933719111415546">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Knipp</surname>
<given-names>GT</given-names>
</name>
</person-group>. <article-title>Expression of PPAR and RXR isoforms in the developing rat and human term placentas</article-title>. <source>Placenta</source>. <year>2002</year>;<volume>23</volume>(<issue>8-9</issue>):<fpage>661</fpage>–<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr17-1933719111415546">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurooka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Honjo</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5</article-title>. <source>J Biol Chem</source>. <year>2000</year>;<volume>275</volume>(<issue>22</issue>):<fpage>17211</fpage>–<lpage>17220</lpage>.</citation>
</ref>
<ref id="bibr18-1933719111415546">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>The SRC family of nuclear receptor coactivators</article-title>. <source>Gene</source>. <year>2000</year>;<volume>245</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr19-1933719111415546">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Nicol</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Fuller-Pace</surname>
<given-names>FV</given-names>
</name>
</person-group>. <article-title>The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner</article-title>. <source>BMC Mol Biol</source>. <year>2004</year>;<volume>5</volume>:<fpage>11</fpage>.</citation>
</ref>
<ref id="bibr20-1933719111415546">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aghajanova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stavreus-Evers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindeberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Landgren</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Sparre</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Hovatta</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Thyroid-stimulating hormone receptor and thyroid hormone receptors are involved in human endometrial physiology</article-title>. <source>Fertil Steril</source>. <year>2011</year>;<volume>95(1)</volume>:<fpage>230</fpage>–<lpage>237</lpage> e232.</citation>
</ref>
<ref id="bibr21-1933719111415546">
<label>21</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nayak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Oviduct and endometrium: cyclic changes in primate oviduct and endometrium</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Knobil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Neill</surname>
<given-names>J</given-names>
</name>
</person-group>, eds. <source>The Physiology of Reproduction</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2005</year>:<fpage>337</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr22-1933719111415546">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vienonen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miettinen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blauer</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Expression of nuclear receptors and cofactors in human endometrium and myometrium</article-title>. <source>J Soc Gynecol Investig</source>. <year>2004</year>;<volume>11</volume>(<issue>2</issue>):<fpage>104</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr23-1933719111415546">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiozawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>2</issue>):<fpage>871</fpage>–<lpage>878</lpage>.</citation>
</ref>
<ref id="bibr24-1933719111415546">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieser</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schneeberger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hudelist</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Endometrial nuclear receptor co-factors SRC-1 and N-CoR are increased in human endometrium during menstruation</article-title>. <source>Mol Hum Reprod</source>. <year>2002</year>;<volume>8</volume>(<issue>7</issue>):<fpage>644</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr25-1933719111415546">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catalano</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Critchley</surname>
<given-names>HO</given-names>
</name>
<name>
<surname>Heikinheimo</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group> <article-title>Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium</article-title>. <source>Mol Hum Reprod</source>. <year>2007</year>;<volume>13</volume>(<issue>9</issue>):<fpage>641</fpage>–<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr26-1933719111415546">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>XF</given-names>
</name>
<name>
<surname>Bagchi</surname>
<given-names>MK</given-names>
</name>
</person-group>. <article-title>Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>15</issue>):<fpage>15050</fpage>–<lpage>15058</lpage>.</citation>
</ref>
<ref id="bibr27-1933719111415546">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodges-Gallagher</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Valentine</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells</article-title>. <source>Breast Cancer Res Treat</source>. <year>2007</year>;<volume>105</volume>(<issue>3</issue>):<fpage>297</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr28-1933719111415546">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krusche</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Vloet</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Classen-Linke</surname>
<given-names>I</given-names>
</name>
<name>
<surname>von Rango</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Beier</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Alfer</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas</article-title>. <source>Hum Reprod</source>. <year>2007</year>;<volume>22</volume>(<issue>11</issue>):<fpage>2956</fpage>–<lpage>2966</lpage>.</citation>
</ref>
<ref id="bibr29-1933719111415546">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talbi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Vo</surname>
<given-names>KC</given-names>
</name>
<etal/>
</person-group> <article-title>Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>3</issue>):<fpage>1097</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr30-1933719111415546">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munro</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Farquhar</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ponnampalam</surname>
<given-names>AP</given-names>
</name>
</person-group>. <article-title>Epigenetic regulation of endometrium during the menstrual cycle</article-title>. <source>Mol Hum Reprod</source>. <year>2010</year>;<volume>16</volume>(<issue>5</issue>):<fpage>297</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr31-1933719111415546">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kashima</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shiozawa</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium</article-title>. <source>Virchows Arch</source>. <year>2010</year>;<volume>456</volume>(<issue>4</issue>):<fpage>433</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr32-1933719111415546">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchikawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shiozawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>HC</given-names>
</name>
<etal/>
</person-group> <article-title>Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression</article-title>. <source>Cancer</source>. <year>2003</year>;<volume>98</volume>(<issue>10</issue>):<fpage>2207</fpage>–<lpage>2213</lpage>.</citation>
</ref>
<ref id="bibr33-1933719111415546">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Richer</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Bain</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Takimoto</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>KB</given-names>
</name>
</person-group>. <article-title>The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT</article-title>. <source>Mol Endocrinol</source>. <year>1997</year>;<volume>11</volume>(<issue>6</issue>):<fpage>693</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr34-1933719111415546">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Leo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schroen</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Characterization of receptor interaction and transcriptional repression by the corepressor SMRT</article-title>. <source>Mol Endocrinol</source>. <year>1997</year>;<volume>11</volume>(<issue>13</issue>):<fpage>2025</fpage>–<lpage>2037</lpage>.</citation>
</ref>
<ref id="bibr35-1933719111415546">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Nawaz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen</article-title>. <source>Mol Endocrinol</source>. <year>1997</year>;<volume>11</volume>(<issue>6</issue>):<fpage>657</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr36-1933719111415546">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Brudney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hastings</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mavrogianis</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Fazleabas</surname>
<given-names>AT</given-names>
</name>
</person-group>. <article-title>The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity</article-title>. <source>Reprod Sci</source>. <year>2007</year>;<volume>14</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr37-1933719111415546">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeMayo</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Takamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SY</given-names>
</name>
</person-group>. <article-title>Mechanisms of action of estrogen and progesterone</article-title>. <source>Ann N Y Acad Sci</source>. <year>2002</year>;<volume>955</volume>:<issue>48-59</issue>; <comment>discussion 86-48, 396-406</comment>.</citation>
</ref>
<ref id="bibr38-1933719111415546">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>DeMayo</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene</article-title>. <source>Science</source>. <year>1998</year>;<volume>279</volume>(<issue>5358</issue>):<fpage>1922</fpage>–<lpage>1925</lpage>.</citation>
</ref>
<ref id="bibr39-1933719111415546">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Silva</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aranda</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation</article-title>. <source>Mol Cell Biol</source>. <year>2004</year>;<volume>24</volume>(<issue>17</issue>):<fpage>7514</fpage>–<lpage>7523</lpage>.</citation>
</ref>
<ref id="bibr40-1933719111415546">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velarde</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Aghajanova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nezhat</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1</article-title>. <source>Endocrinology</source>. <year>2009</year>;<volume>150</volume>(<issue>10</issue>):<fpage>4701</fpage>–<lpage>4712</lpage>.</citation>
</ref>
<ref id="bibr41-1933719111415546">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nicol</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hislop</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Jaffray</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Fuller-Pace</surname>
<given-names>FV</given-names>
</name>
</person-group>. <article-title>SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>(<issue>40</issue>):<fpage>5866</fpage>–<lpage>5876</lpage>.</citation>
</ref>
<ref id="bibr42-1933719111415546">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuller-Pace</surname>
<given-names>FV</given-names>
</name>
</person-group>. <article-title>DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation</article-title>. <source>Nucleic Acids Res</source>. <year>2006</year>;<volume>34</volume>(<issue>15</issue>):<fpage>4206</fpage>–<lpage>4215</lpage>.</citation>
</ref>
<ref id="bibr43-1933719111415546">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Masuhiro</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha</article-title>. <source>Mol Cell Biol</source>. <year>1999</year>;<volume>19</volume>(<issue>8</issue>):<fpage>5363</fpage>–<lpage>5372</lpage>.</citation>
</ref>
<ref id="bibr44-1933719111415546">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Coulson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dalgliesh</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer</article-title>. <source>Cancer Res</source>. <year>2008</year>;<volume>68</volume>(<issue>19</issue>):<fpage>7938</fpage>–<lpage>7946</lpage>.</citation>
</ref>
<ref id="bibr45-1933719111415546">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>ZR</given-names>
</name>
</person-group>. <article-title>Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter</article-title>. <source>Oncogene</source>. <year>2010</year>;<volume>29</volume>(<issue>39</issue>):<fpage>5427</fpage>–<lpage>5436</lpage>.</citation>
</ref>
<ref id="bibr46-1933719111415546">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos-Rosa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Caldas</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Chromatin modifier enzymes, the histone code and cancer</article-title>. <source>Eur J Cancer</source>. <year>2005</year>;<volume>41</volume>(<issue>16</issue>):<fpage>2381</fpage>–<lpage>2402</lpage>.</citation>
</ref>
<ref id="bibr47-1933719111415546">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoo</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>Down-regulation of histone deacetylases stimulates adipocyte differentiation</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>10</issue>):<fpage>6608</fpage>–<lpage>6615</lpage>.</citation>
</ref>
<ref id="bibr48-1933719111415546">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>SW</given-names>
</name>
</person-group>. <article-title>Epigenetics of endometriosis</article-title>. <source>Mol Hum Reprod</source>. <year>2009</year>;<volume>15</volume>(<issue>10</issue>):<fpage>587</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr49-1933719111415546">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Arici</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Olive</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>101</volume>(<issue>7</issue>):<fpage>1379</fpage>–<lpage>1384</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>